[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-neuroendocrine-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-neuroendocrine-tumor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,48,75,98,128,168,198,227,250,277,300,324,351],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100433434","phase-2-belzutifanmk-6482-for-the-treatment-of-advanced-pheochromocytomaparaganglioma-ppgl-pancreatic-neuroendocrine-tumor-pnet-von-hippel-lindau-vhl-disease-associated-tumors-advanced-gastrointestinal-stromal-tumor-wt-gist-or-solid-tumors-with-hif-2-related-genetic-alterations-mk-6482-015-100433434",false,"NCT04924075","Belzutifan\u002FMK-6482 for the Treatment of Advanced Pheochromocytoma\u002FParaganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma\u002FParaganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations","The main inclusion criteria include but are not limited to the following:\n\n* Male and female participants at least 12 years of age (at least 18 years of age for Cohort B1)\n* Diagnosis of one of the following: Advanced\u002Fmetastatic pheochromocytoma\u002Fparaganglioma (PPGL), pancreatic neuroendocrine tumors (pNET), von Hippel-Lindau (VHL) disease associated localized tumors, or advanced wild-type gastrointestinal stromal tumor (wt GIST) or advanced solid tumors with Hypoxia Inducible Factor- 2 alpha subunit (HIF-2α) related genetic alterations\n* Cohort B1: VHL Disease-associated tumors:\n\n  * Have a diagnosis of VHL disease as determined by a germline test locally and\u002For clinical diagnosis\n  * Must be ≥18 years of age\n* Has a life expectancy of at least 3 months\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Unable to swallow orally administered medication or has a disorder that might affect the absorption of belzutifan\n* History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years\n* Any of the following: A pulse oximeter reading \\\u003C92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen\n* Clinically significant cardiac disease, including unstable angina, acute myocardial infarction, or arterial bypass (CABG) or Percutaneous transluminal coronary angioplasty (PTCA) ≤6 months from study entry, or New York Heart Association Class III or IV congestive heart failure\n* Received prior treatment (except somatostatin analogs) with chemotherapy, targeted therapy, biologics, or other investigational therapy within the past 4 weeks of first dose of study intervention","ALL","12 Years",{"count":19,"type":20},355,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma\u002Fparaganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).",[26,27,28,29,30],"Pheochromocytoma\u002FParaganglioma","Pancreatic Neuroendocrine Tumor","Von Hippel-Lindau Disease","Advanced Gastrointestinal Stromal Tumor","HIF-2α Mutated Cancers",[32,33,34],"HIF-2α","Pheochromocytoma\u002Fparaganglioma","Pancreatic NET","RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-26","ACTUAL",{"date":41,"type":39},"2021-08-12",{"date":43,"type":20},"2029-12-27",{"name":45,"class":46},"Merck Sharp & Dohme LLC","INDUSTRY",84,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100637717","endoscopic-ultrasound-guided-pulsed-electric-field-ablation-for-the-treatment-of-pancreatic-neoplasms-100637717","NCT07619417","Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms","Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation of Pancreatic Neoplasms - A Safety and Feasibility Trial","Inclusion Criteria:\n\n* Age \\> 18 years\n* A diagnosis of a pancreatic neoplasm confirmed by EUS-fine needle aspiration (FNA) - (a) pancreatic cystic lesion such as intraductal papillary-mucinous neoplasm (IPMN), (b) World Health Organization (WHO) grade I neuroendocrine tumor\n* Lesion size estimation by computed tomography (CT) or magnetic resonance imaging (MRI)\u002Fmagnetic resonance cholangiopancreatography (MRCP) or EUS: (a) pancreatic cystic lesion such as IPMN - at least 2 cm in diameter. (b) WHO grade I neuroendocrine tumor - at least 1 cm in diameter\n* The patient is not a surgical candidate. Common clinical scenarios include -\n\n  * Cirrhosis of the liver (common clinical scenario)\n  * Advanced (≥ 75 years) age (common clinical scenario)\n  * Morbid obesity\n  * Significant cardiorespiratory comorbidity\n  * Patient's choice (patient elects for non-surgical management)\n  * Other significant comorbid conditions that impose prohibitive surgical risks\n  * The patient prefers non-surgical management after consultation with hepato-pancreato-biliary (HPB) surgery\n* For pancreatic neuroendocrine tumor (PNET) and all pancreatic cystic lesions (PCLs): Estimated life expectancy of at least 1 year\n* Capable of giving written informed consent or has a legally authorized representative (LAR) to consent for them\n* Women of childbearing potential must have a negative pregnancy test (serum\u002Furine) on the day of treatment. Pregnancy testing is the routine standard of care practice in the endoscopy laboratory for all patients undergoing endoscopy and sedation for endoscopy\n* The patient is not a surgical candidate and has had prior attempts at ablation of the PCN by EUS-RFA (Ohio State University \\[OSU\\] Institutional Review Board \\[IRB\\] protocol: 2023C0004)\n\nExclusion Criteria:\n\n* Any evidence of severe or uncontrolled systemic diseases, or laboratory findings that, in the investigator's opinion, make it unsafe for the patient to participate in the study study\n* Pregnancy or breast-feeding\n* Clinical frailty scale\n* Contraindication to general anesthesia after review by OSU Preoperative Assessment Clinic (OPAC)","18 Years",{"count":57,"type":20},12,[59],"NA","This clinical trial tests the safety and feasibility of endoscopic ultrasound-guided pulsed electric field ablation for the treatment of pancreatic neoplasms. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage. The approach for pancreatic neoplasm treatment has changed and the recognition of minimally invasive treatments is growing. One such minimally invasive treatment, known as endoscopic ultrasound-guided pulsed electric field ablation, offers an alternative to surgery for managing certain precancerous or high-risk pancreatic cysts. The Aliya Pulsed Electric Field system uses brief, strong bursts of electricity, delivered through a thin needle, to destroy targeted tissue, such as tumors, without using heat. These electric pulses damage only the cells inside the treatment zone, leaving the healthy tissues and important nearby structures unharmed. This makes the treatment safer and less likely to cause harm to sensitive areas around the tumor. Endoscopic ultrasound-guided pulsed electric field ablation may be safe and feasible for the treatment of pancreatic neoplasms.",[62,27],"Pancreatic Neoplasm","NOT_YET_RECRUITING","2026-05-27",{"date":66,"type":39},"2026-06-02",{"date":68,"type":20},"2026-08-01",{"date":70,"type":20},"2027-12-31",{"name":72,"class":73},"Ohio State University Comprehensive Cancer Center","OTHER",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":74},"100526947","treatment-of-advanced-endocrine-tumor-with-iindividualized-mrna-neoantigen-vaccine-mrna-0523-l001-100526947","NCT06141369","Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)","Inclusion Criteria:\n\n1. The subjects voluntarily sign the written informed consent form and can comply with the visits and related procedures specified in the protocol;\n2. The subjects are 18 years old or older, regardless of gender;\n3. Patients with advanced endocrine tumors confirmed by histology or cytology in the past 6 months (including medullary thyroid carcinoma, thymic carcinoma and adrenal cortical carcinoma, etc.), who have failed standard treatment or have no standard treatment available;\n4. No HLA-related genes or chromosomal regions with copy number variations (CNVs) or loss of heterozygosity (LOH) were detected by gene sequencing;\n5. They have advanced or metastatic lesions confirmed by immunohistochemistry, and have frozen tissue\u002Fcells sufficient for WES and RNAseq sequencing, and after bioinformatics analysis, they predict at least one antigen that is effectively presented by their own HLA, such as KRAS or TP53 mutations and corresponding HLA typing, see 1.4 for the rationale of the topic.\n6. Expected survival ≥ 4 months;\n7. According to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), they have at least one measurable lesion, which should not have received local treatment such as radiotherapy (lesions in the previous radiotherapy area, if confirmed to have progressed, can also be selected as target lesions);\n8. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1;\n9. They have not used granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), red blood cell transfusion or platelet transfusion within 14 days before the examination.\n10. Subjects of childbearing potential (male and female) who meet the inclusion criteria must agree to use reliable contraception methods (hormonal or barrier methods or abstinence) during the trial and for at least 90 days after the last administration; women of childbearing age must have a negative blood pregnancy test within 7 days before the first administration.\n11. Virology test: No CMV, EBV, HIV, HBV, HCV, syphilis infection (only at baseline)\n\nExclusion Criteria:\n\n1. Received chemotherapy, hormone therapy, traditional Chinese medicine with anti-tumor indications or other anti-tumor treatments within 4 weeks before the first administration (for mitomycin and nitrosourea, the last administration was within 6 weeks before the first administration of this study drug), or within 5 half-lives of immunotherapy or molecular targeted therapy;\n2. Received other major surgery other than diagnosis or biopsy within 4 weeks before the first administration, or expected to receive major surgery during the study;\n3. Patients who have received allogeneic hematopoietic stem cell transplantation or organ transplantation in the past, or plan to receive organ transplantation during this study;\n4. Patients who have received other tumor vaccines or cell therapies in the past; Medical condition\n5. Patients with clinically symptomatic brain metastases, spinal cord compression, carcinomatous meningitis, or other evidence indicating that the patient's brain or spinal cord metastases are not controlled, and are deemed unsuitable for enrollment by the investigator;\n6. In the past 2 years, there have been known other malignant tumors that are progressing or require active treatment (except for non-melanoma skin cancer, superficial bladder cancer, and cervical carcinoma in situ that have been cured by radical surgery);\n7. Have a history of interstitial lung disease (ILD) or pulmonary interstitial fibrosis;\n8. Have a history of severe cardiovascular and cerebrovascular diseases, including but not limited to: a) Have severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block; corrected QTc interval male \\> 450 milliseconds, female \\> 470 milliseconds, b) Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other grade 3 or higher cardiovascular and cerebrovascular events occurred within 6 months before the first administration, c) New York Heart Association (NYHA) ≥ III grade heart failure or left ventricular ejection fraction (LVEF) \\\u003C50%.\n9. Other serious and\u002For uncontrollable diseases that may affect the subject's participation in this study, as determined by the investigator, including but not limited to: a) Have a history of severe drug allergy, or known to be allergic to any component of the tumor vaccine; or have had a severe allergic reaction to other monoclonal antibodies in the past, b) Have a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, c) Evidence of severe or uncontrolled liver or kidney disease, d) Poorly controlled hypertension, diabetes, etc., e) Patients with active ulcers or gastrointestinal bleeding f) Have a severe infection that requires intravenous infusion of antibiotics or hospitalization; or uncontrolled active infection within 4 weeks before the first administration, g) Have active syphilis infection.\n10. Participated in other clinical trials within 4 weeks before the first administration (except for screening failure);\n11. Currently receiving systemic use of corticosteroids (except for recent or current use of inhaled corticosteroids);\n12. Pregnant or lactating women; Laboratory and imaging examinations\n13. Imaging (CT or MRI) shows that the tumor invades the large blood vessels and has a tendency to bleed;\n14. Have clinically significant thyroid function abnormalities, and the investigator deems them unsuitable for enrollment;\n15. Active pneumonia was found in the screening chest CT scan;\n16. Uncontrolled pleural effusion, pericardial effusion, or ascites that requires repeated drainage;\n17. The adverse reactions of previous anti-tumor treatment have not recovered to NCI-CTCAE 5.0 grade evaluation ≤ 1 (except for hair loss);\n18. Hepatitis B surface antigen (HBsAg) positive and peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) test value higher than the upper limit of normal; hepatitis C virus antibody (HCV Ab) positive and HCV RNA test value higher than the upper limit of normal; Investigator assessment\n19. The investigator considers that there are other reasons that are not suitable for participating in the clinical trial.",{"count":82,"type":20},21,[59],"Treatment of advanced endocrine tumors, including adrenal corticocarcnioma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine tumor and pancreatic neuroendocrine tumor is challenging. Previous genomic profiling studies showed they presented a number of somatic mutations. The tumors Individualized mRNA neoantigen vaccine provide a promising solution since a significant portion of these tumors showed high quality of tumor specific neoantigen. The primary objective is to observe and evaluate the safety and tolerability of individualized mRNA neoantigen vaccine (mRNA-0523-L001) for the treatment of advanced endocrine tumors, failure of standard treatment or no standard treatment currently available. The secondary objective is to observe the preliminary efficacy of mRNA-0523-L001 for the treatment of advanced endocrine tumors, failure of standard treatment or no standard treatment currently available, including:\n\n1. Neoantigen-specific CD4+ and CD8+ T lymphocyte responses induced by mRNA-0523-L001;\n2. Objective response rate (ORR) and disease control rate (DCR) of tumors;\n3. Progression-free survival (PFS).",[86,87,88,27],"Adrenal Cortical Carcinoma","Medullary Thyroid Cancer","Thymic Neuroendocrine Carcinoma","2026-04-05",{"date":91,"type":39},"2026-04-09",{"date":93,"type":39},"2024-01-13",{"date":95,"type":20},"2027-06-30",{"name":97,"class":73},"Shanghai Jiao Tong University School of Medicine",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100504403","plasma-cfdna-fragmentomics-for-early-pnet-detection-and-differential-diagnosis-of-solid-pancreatic-tumors-100504403","NCT05847855","Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors","A Prospective Study of Plasma Cell-free DNA Fragmentomics for Early Detection of Pancreatic Neuroendocrine Tumors and Differential Diagnosis of Solid Pancreatic Tumors","Inclusion Criteria:\n\n* Age 18 and above, regardless of gender;\n* Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;\n* Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;\n* No obvious surgical contraindications;\n* Able to comply with research plans, follow-up plans, and other protocol requirements;\n* Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n* Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;\n* Currently diagnosed with other types of tumors or any cancer history;\n* Diagnosed with familial syndromes;\n* Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;\n* Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw;\n* Recipient of blood transfusion within 30 days prior to study blood draw;\n* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;\n* Poor health condition and not suitable for blood draw;\n* Any other disease\u002Fcondition deemed not suitable for study enrollment by researcher.",true,{"count":107,"type":20},1000,"OBSERVATIONAL","This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.",[27,111],"Solid Pancreatic Neoplasms",[113,114,115,116,117],"Pancreatic neuroendocrine tumor","cell-free DNA","fragmentomics","early detection","Solid pancreatic neoplasms","2026-03-23",{"date":120,"type":39},"2026-03-25",{"date":122,"type":39},"2023-02-27",{"date":124,"type":20},"2026-06-30",{"name":126,"class":73},"Fudan University",2,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100371641","phase-1-gene-modified-immune-cells-after-conditioning-regimen-for-the-treatment-of-stage-iiic-or-iv-melanoma-or-metastatic-solid-tumors-100371641","NCT04119024","Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors","Inclusion Criteria:\n\n* Histologically confirmed malignancy that is considered surgically incurable with either:\n\n  * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis\n  * Stage IV melanoma including patients with known brain metastases\n  * Other metastatic, non-central nervous system (CNS) solid tumor relapsed or refractory after all standard-of-care systemic therapies for which the patient is eligible\n* Confirmed IL13Ralpha2 tumor expression by immunohistochemistry (immunohistochemical assay \\[IHA\\] H-Score \\>= 50 in at least 10% of the total tumor specimen and in at least two high-power fields)\n* Age greater than or equal to 18 years old and less than 75 years old\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* A minimum of one measurable lesion defined as:\n\n  * Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), OR\n  * Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)\n* Absolute neutrophil count (ANC) \\>= 1 x 10\\^9 cells\u002FL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Platelets \\>= 75 x 10\\^9\u002FL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Hemoglobin \\>= 9.5 g\u002FdL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Aspartate and alanine aminotransferases (AST, ALT) =\\\u003C 2.5 x upper limit of normal (ULN) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Total bilirubin =\\\u003C 2 x ULN (except patients with documented Gilbert's syndrome) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Creatinine \\\u003C 2 mg\u002FdL (or a glomerular filtration rate \\> 45) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Patients with melanoma must have progressed following \\>= 1 line of systemic therapy, including immune checkpoint inhibitor and a BRAF inhibitor in combination with MEK inhibitor for patients with BRAF V600-activating mutation and is not considered to have an alternate treatment option with curative intent\n* Must be willing and able to accept at least one leukapheresis procedure (This does not apply for patients receiving a second infusion of IL13R a2 CAR T cells as they will not undergo leukapheresis)\n* Must be willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to purify \\>= 1 x 10\\^7 T cells from leukapheresis product (this does not apply to patients receiving a second infusion of IL13Ra2 CAR T cells as they will not undergo leukapheresis)\n* Previously known hypersensitivity to any of the agents used in this study; known sensitivity to cyclophosphamide or fludarabine\n* Received systemic treatment for cancer, including immunotherapy, within 14 days prior to initiation of conditioning chemotherapy administration within this protocol\n* Clinically active brain metastases. Radiological documentation of absence of active brain metastases at screening is required for all patients. Prior evidence of brain metastasis successfully treated with surgery or radiation therapy will not be exclusion for participation as long as they are deemed under control at the time of study enrollment\n* Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 2 weeks prior to enrollment; not including patients with primary or secondary adrenal insufficiency who require physiologic replacement with steroids, or patients on inhaled or topical steroids at standard doses\n* Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion. If there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and\u002For infectious disease specialist\n* Hepatitis B or C seropositivity with evidence of ongoing liver damage, which would increase the likelihood of hepatic toxicities from the chemotherapy conditioning regimen and supportive treatments. If there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and\u002For infectious disease specialist\n* Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol\n* A Tiffeneau-Pinelli index \\\u003C 70% of the predicted value. Subjects will be excluded if pulmonary function tests indicate they have insufficient pulmonary capability\n* Patients will be excluded if they have a history of clinically significant electrocardiography (ECG) abnormalities, symptoms of cardiac ischemia or arrhythmias and have a left ventricular ejection fraction (LVEF) \\\u003C 45% on a cardiac stress test (stress thallium, stress multigated acquisition scan (MUGA), dobutamine echocardiogram, or other stress test)\n* Patients with ECG results of any conduction delays (PR interval \\> 200 ms, corrected QT (QTC) \\> 480 ms), sinus bradycardia (resting heart rate \\\u003C 50 beats per minute), sinus tachycardia (HR \\> 120 beats per minute) will be evaluated by a cardiologist prior to starting the trial. Patients with any arrhythmias, including atrial fibrillation\u002Fatrial flutter, excessive ectopy (defined as \\> 20 ventricular premature complex \\[PVC\\]s per minute), ventricular tachycardia, 3rd degree heart block will be excluded from the study unless cleared by a cardiologist\n* Pregnancy or breast-feeding. Female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and for 6 months afterwards. All female patients with reproductive potential must have a negative pregnancy test (serum\u002Furine) at screening and again within 14 days from starting the conditioning chemotherapy. The definition of effective contraception will be based on the judgment of the study investigators. Patients who are breastfeeding are not allowed on this study\n* A concomitant active malignancy that would be considered to interfere with the assessment of the primary or secondary endpoints of the study","75 Years",{"count":137,"type":20},18,[139],"PHASE1","This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patient's own blood, grown in a laboratory, and modified by adding the IL13Ralpha2 CAR gene. The IL13Ralpha2 CAR gene is inserted into T cells with a virus called a lentivirus. The lentivirus allows cells to make the IL13Ralpha2 CAR protein. This CAR has been designed to bind to a protein on the surface of tumor cells called IL13Ralpha2. This study is being done to determine the dose at which the gene-modified immune cells are safe, how long the cells stay in the body, and if the cells are able to attack the cancer.",[142,143,144,145,146,147,148,149,150,151,152,153,27,154,155,156,157],"Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Recurrent Malignant Solid Neoplasm","Refractory Malignant Solid Neoplasm","Uveal Melanoma","Acral Melanoma","Neuroendocrine Tumors","Paraganglioma","Pheochromocytoma","Adrenocortical Carcinoma","Thyroid Cancer","Breast Cancer","Lung Adenocarcinoma","Head and Neck Squamous Cell Carcinoma","2026-03-13",{"date":160,"type":39},"2026-03-17",{"date":162,"type":39},"2025-10-07",{"date":164,"type":20},"2026-10",{"name":166,"class":73},"Anusha Kalbasi",3,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":175,"enrollmentInfo":176,"targetDuration":178,"studyType":108,"phases":4,"briefSummary":179,"conditions":180,"keywords":187,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":74},"100626755","ai-powered-precision-decision-making-for-pancreatic-diseases-100626755","NCT07439757","AI-Powered Precision Decision-Making for Pancreatic Diseases","A Multicenter Clinical Study on AI-Powered Precision Decision-Making Management for Pancreatic Diseases Using Contrast-Enhanced CT","Inclusion Criteria:\n\n* Clinically suspected pancreatic disease.\n* Scheduled to undergo contrast-enhanced CT.\n* Signed informed consent form indicating agreement to participate.\n\nExclusion Criteria:\n\n* History of pancreatic surgery.\n* Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal\u002Fhepatic dysfunction.\n* Suboptimal image quality affecting diagnosis.\n* Concurrent participation in another interventional clinical trial.\n* Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.","80 Years",{"count":177,"type":20},2000,"1 Year","This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery\u002Ftreatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.",[181,182,183,184,185,27,186],"Pancreatic Cancer","Diagnose Disease","IPMN, Pancreatic","Pancreatic Cystic Lesions","Chronic Pancreatitis","Acute Pancreatitis (AP)",[188],"Artificial Intelligence (AI), Deep Learning, Contrast-Enhanced CT, Multicenter Clinical Trial, Real-World Study","2026-02-23",{"date":191,"type":39},"2026-02-27",{"date":193,"type":20},"2026-03-01",{"date":195,"type":20},"2029-10-31",{"name":197,"class":73},"Changhai Hospital",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100613962","pancreatic-neuroendocrine-tumour---optimal-surgical-debulking-or-not-100613962","NCT07273409","Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not","PANcreatic Neuroendocrine Tumour - Optimal Surgical Debulking Or Not (PANTODON). A Prospective, Two Armed, Parallel, Randomised, Controlled International Multicentre Study on WHO Grade 1-2, Stage 4 Pancreatic NET","PANTODON","Inclusion Criteria:\n\n* Pan- NET, ENETS\u002FAJCC stage 4 determined by CT or PET\u002FCT\n* Primary tumour or metastases confirmed as Pancreatic NET GI-WHO grade 1-2 pan-NET by histology or cytology\n* Age ≥ 18 years\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Subject not fit for surgery due to comorbidity or advanced age (reason to be specified)\n* Risk of surgery deemed too high by MDT or Surgeon (reason to be specified)\n* Previous surgery for pan-NET.\n* Hormonal symptoms caused by a functional pan-NET, not controllable by medical therapy, indicating debulking surgery.\n* Previously included in the current study.\n* Pregnancy\n* The study subject does not fit into either STRATA: a) STRATUM 1: Less than 70% of the total tumour volume can be debulked, b) STRATUM 2: no FDG-PET avid disease is observed OR all (100%) FDG-PET avid tumour is not resectable.\n* Other reason in the opinion of the Principal Investigator (reason to be specified).",{"count":207,"type":20},200,[59],"Pancreatic neuroendocrine tumours (pan-NETs) are neoplasms arising from the endocrine cells of the pancreas. Although pan-NET are quite rare, the incidence is on the rise and together with other abdominal neuroendocrine tumours an approximate incidence in Sweden would be 850 patients per year extrapolating from Norwegian data. Pan-NET are divided into symptomatic hormone producing tumours (such as insulinomas\u002Fglucagonomas\u002FVIPomas) or non-functioning tumours that often are asymptomatic. As early symptoms often are lacking in non-functioning-pan-NET, many patients present with distant metastases and are thus beyond a curative surgical approach at the time of diagnosis. Metastatic non-functioning pan-NETs present a significant challenge and the optimal management remains a subject of debate.\n\nThis is a prospective, two armed, parallel, randomised, controlled, international multi-centre study, aiming to investigate if a near-total tumour debulking (intervention) in metastatic (stage 4) GI-WHO grade 1-2 pan- NET, with or without oncologic treatment, is superior to oncologic treatment alone (control), with regards to overall survival, health-related quality of life, participant performance status, time until hospitalisation, adverse event characteristics and cost in the short and long term.",[27],[212,213,214,215,216],"Pan-NET","Stage 4","Debulking surgery","Non-functional Pan-NET","GI-WHO grade 1-2 Pan-NET","2026-01-21",{"date":219,"type":39},"2026-01-22",{"date":221,"type":39},"2026-01-09",{"date":223,"type":20},"2033-05-31",{"name":225,"class":73},"Uppsala University",4,{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":135,"enrollmentInfo":234,"targetDuration":4,"studyType":21,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":246,"leadSponsor":248,"locationsCount":74},"100618206","outcomes-after-laparoscopic-versus-open-pancreaticoduodenectomy-100618206","NCT07328607","Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy","Open Versus Laparoscopic Pancreaticoduodenectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed or clinically suspected lesions of: Pancreatic head adenocarcinoma, Ampullary carcinoma, Distal cholangiocarcinoma, Duodenal adenocarcinoma, Pancreatic neuroendocrine tumors, or Intraductal Papillary Mucinous Neoplasm(IPMN) .\n* Resectable disease based on preoperative imaging.\n* Eastern Cooperative Oncology Group(ECOG) performance status 0-2.\n* American Society of Anesthesiologists(ASA )classification I-III.\n* Patients able to provide informed consent.\n\nExclusion Criteria:\n\n* Emergency surgery.\n* Previous pancreatic surgery.\n* Concurrent major abdominal procedures .\n* ASA classification IV or higher.\n* Metastatic disease identified preoperatively.\n* Locally advanced unresectable disease.\n* Active infection or sepsis at time of surgery.\n* Severe cardiopulmonary comorbidities precluding major surgery.\n* Pregnancy.\n* Procedures requiring Total Pancreatectomy, Distal Pancreatectomy, or Enucleation .",{"count":235,"type":20},90,[59],"This is a monocentric, prospective, randomized controlled trial comparing the safety and efficacy of laparoscopic pancreaticoduodenectomy (LPD) versus open pancreaticoduodenectomy (OPD). The study aims to determine the morbimortality of the laparoscopic approach compared to the gold standard open approach in adult patients with pancreatic or periampullary lesions.",[239,240,241,242,27],"Pancreatic Ductal Adenocarcinoma","Ampullary Carcinoma","Distal Cholangiocarcinoma","Duodenal Adenocarcinoma","2026-01-17",{"date":217,"type":39},{"date":243,"type":39},{"date":247,"type":20},"2028-04-15",{"name":249,"class":73},"Minia University",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":21,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":276},"100442359","phase-2-testing-the-use-of-chemotherapy-after-surgery-for-high-risk-pancreatic-neuroendocrine-tumors-100442359","NCT05040360","Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors","Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors","Inclusion Criteria:\n\n* Participants must have a histologic diagnosis of well-differentiated pancreatic neuroendocrine tumor (pNET) that was resected between 14 and 120 days prior to registration. Participants must have a scan within 90 days prior to registration without evidence of metastatic disease. Acceptable scans are multiphase computed tomography (CT) abdomen, magnetic resonance imaging (MRI) with intravenous (IV) contrast of the abdomen, or positron emission tomography (PET)-CT DOTATATE imaging if the DOTATATE PET-CT included IV iodine contrast for the CT portion of the exam\n* Resection must have been an R0 or R1 per treating investigator's assessment and\u002For pathology report\n* Ki-67 testing, which is considered part of standard of care in the pathology report, must have been performed between 14 and 90 days prior to registration and the result must be \\>= 3% and =\\\u003C 55%. Treating investigators are encouraged to contact the S2104 Study Chairs and\u002For the study pathology chair with questions. If more than one Ki-67 is reported (e.g., primary tumor versus lymph node or metastatic site), the highest one should be considered for the study eligibility criteria\n* Participants with localized resected pNETS must have a Zaidi score of \\>= 3 derived by the following factors and points:\n\n  * 1 point; symptomatic tumor defined as one of the following:\n\n    * Gastrointestinal bleed\n    * Jaundice\n    * Gastrointestinal obstruction\n    * Pain from primary tumor prior to surgical resection\n    * Pancreatitis\n  * 2 points; primary pancreas tumor size \\> 2 cm\n  * 1 point; Ki-67 3% to 20%\n  * 1 point; lymph node positivity = 1\n  * 6 points; Ki-67 21% to 55%\n* Participants may have received resection\u002Fablation of liver oligo-metastatic disease (up to 5 liver metastases) at the time of well-differentiated pNET resection\n* Participants must have recovered from effects of surgery as determined by the treating investigator\n* Participants must be \\>= 18 years old\n* Participants must have Zubrod performance status of 0-2\n* Participants must have a complete medical history and physical exam within 28 days prior to registration\n* Leukocytes \\>= 3 x 10\\^3\u002FuL (within 28 days prior to registration)\n* Absolute neutrophil count \\>= 1.5 x 10\\^3\u002FuL (within 28 days prior to registration)\n* Platelets \\>= 100 x 10\\^3\u002FuL (within 28 days prior to registration)\n* Total bilirubin =\\\u003C institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\\\u003C 5 x institutional ULN (within 28 days prior to registration)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\\u003C 3 x institutional ULN (within 28 days prior to registration)\n* Serum creatinine =\\\u003C 1.5 x institutional ULN (within 28 days prior to registration)\n* Calculated creatinine clearance \\>= 50 ml\u002Fmin (within 28 days prior to registration)\n* Participants must be able to swallow pills\n* Participants must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for their treatment and the protocol\n* No other active malignancy or history of prior malignancy is allowed, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years\n* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines\n\nExclusion Criteria:\n\n* Participants must not have unresected or unablated metastatic disease\n* Participants must not have clinically apparent central nervous system metastases or carcinomatous meningitis\n* Participants must not have received prior neoadjuvant therapy for treatment of pancreatic neuroendocrine tumor. Use of somatostatin analogs prior to surgery is permitted\n* Participants must not have received somatostatin analogs after surgery\n* Participants must not be planning to receive warfarin while on protocol treatment. Other anticoagulants are allowed\n* Participants must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or capecitabine\n* Participants must not have known absorption issues that would limit the ability to absorb study agents\n* Participants must not have had an arterial thromboembolic event, unstable angina, or myocardial infarction within 12 months prior to registration\n* Participants must not have active or uncontrolled infection\n* Participants must not have serious medical or psychiatric illness that could affect study participation in the judgement of the treating investigator\n* Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of \"reproductive potential.\" In addition to routine contraceptive methods, \"effective contraception\" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation\u002Focclusion, and vasectomy with testing showing no sperm in the semen",{"count":258,"type":20},141,[23],"This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.",[262,27,263,264,265],"Metastatic Malignant Neoplasm in the Liver","Stage I Pancreatic Neuroendocrine Tumor AJCC v8","Stage II Pancreatic Neuroendocrine Tumor AJCC v8","Stage III Pancreatic Neuroendocrine Tumor AJCC v8","2025-12-10",{"date":268,"type":39},"2025-12-15",{"date":270,"type":39},"2022-05-05",{"date":272,"type":20},"2027-03-31",{"name":274,"class":275},"SWOG Cancer Research Network","NETWORK",448,{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":74},"100525429","development-of-new-personalised-3d-preclinical-models-of-pancreatic-neuroendocrine-tumours-100525429","NCT06121622","Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours","3DPanNET","Inclusion criteria:\n\n* patients who undergo pancreatic surgical resection for non-functioning pancreatic neuroendocrine tumor\n* age ≥ 18 years\n* informed consent\n\nExclusion criteria:\n\n* non-pancreatic neuroendocrine tumor histological diagnosis\n* age \\\u003C 18 years",{"count":285,"type":20},70,"The goal of this prospective observational study is to generate new personalised 3D preclinical models of pancreatic neuroendocrine tumors. The models will be exploited for studying the mechanisms underlying disease development and progression, as well as for performing drug testing. For the development of the newly proposed models, patients' surgical specimens will be evaluated by the Pathological Unit. If the presence of pathological material in excess, not required for the routine diagnostic procedure, is confirmed, such material will be employed for the generation of the proposed personalised models.",[27],[289,290],"PanNET","3D preclinical models","2025-04-28",{"date":293,"type":39},"2025-05-01",{"date":295,"type":39},"2024-01-16",{"date":297,"type":20},"2029-12",{"name":299,"class":73},"IRCCS San Raffaele",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":105,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":74},"100519243","pancreatic-cancer-screening-through-the-detection-of-elastase-1-combined-with-other-examinations-100519243","NCT06041009","Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations","Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations: A Multicenter, Prospective, Diagnostic Clinical Cohort Study.","Inclusion Criteria:\n\nCase groups (matching any of the following):\n\n1. Patients with pancreatic cancer with recognized diagnostic criteria or conclusions.\n2. Patients who are the high-risk group of pancreatic cancer.\n3. Patients with solid pseudo papilloma and neuroendocrine tumors of pancreas with recognized diagnostic criteria or conclusions.\n4. Patients with other diseases with abnormally elevated CA19-9.\n\nControl group:\n\n(1) Patients without pancreatic disease assessed by laboratory tests and imaging examinations have no CA19-9 elevation.\n\nExclusion Criteria:\n\n1. Patients who are younger than 18 years of age.\n2. Patients with suspected pancreatic malignant lesions but has no confirmed imaging or pathological diagnosis.\n3. Patients who have not signed informed consent.",{"count":308,"type":20},2100,"This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients with CA19-9 elevation and controls without pancreatic disease. This study aims to establish a diagnostic prediction model by using elastase 1, common clinical serological examinations, and imaging examinations including endoscopic ultrasonography (EUS), and to explore the diagnostic ability of the model in the high-risk population of PDAC. Besides, the investigators search for new biomarkers by multi-omics studies of serum and pancreatic tissues to further improve the diagnostic performance of this model. In conclusion, this study seeks a robust diagnostic prediction model to diagnose PDAC, especially early resectable PDAC.",[239,311,312,27,313,314],"Pancreatic Diseases","Pancreatic Elastase 1","Pancreatitis","Pancreatic Neoplasms","2024-10-16",{"date":317,"type":39},"2024-10-18",{"date":319,"type":39},"2023-05-05",{"date":321,"type":20},"2025-09-30",{"name":323,"class":73},"Qilu Hospital of Shandong University",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":21,"phases":332,"briefSummary":333,"conditions":334,"keywords":338,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":226},"100515864","phase-2-trial-of-nab-sirolimus-in-patients-with-well-differentiated-neuroendocrine-tumors-nets-of-the-gastrointestinal-tract-lung-or-pancreas-who-have-not-received-prior-treatment-with-mtor-inhibitors-100515864","NCT05997056","Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors","A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors","Inclusion Criteria:\n\n1. Patients with functional or non-functional, well-differentiated, locally advanced unresectable or metastatic NETs of the GI tract, lung, or pancreas who have received 2 or less prior lines of therapy excluding somatostatin analogs\n2. Patients with functional NETs may enroll if:\n\n   1. the patient has been on a stable dose of an somatostatin analogs for ≥12 weeks and\n   2. the patient has experienced disease progression while on stable somatostatin analogs dose\n3. Patients must have 1 or more measurable target lesions by RECIST v1.1\n4. Age: 18 years or older\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or Karnofsky Performance Status (KPS) ≥80\n6. Adequate liver function:\n\n   1. Total bilirubin ≤1.5 × upper limit of normal (ULN) (unless due to Gilbert's syndrome or attributable to liver metastases, then ≤3 × ULN)\n   2. Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases)\n7. Adequate renal function: creatinine clearance ≥30 mL\u002Fmin, Cockcroft-Gault creatinine clearance = ((140-age) × weight\\[kg\\]) \u002F (72 × serum creatinine \\[mL\u002Fmin\\]) × 0.85, if female.\n8. Adequate hematologic parameters:\n\n   1. Absolute neutrophil count (ANC) ≥1.0 × 10\\^9\u002FL (growth factor support allowed)\n   2. Platelet count ≥100,000\u002Fmm\\^3 (100 × 10\\^9\u002FL) (transfusion and\u002For growth factor support allowed)\n   3. Hemoglobin ≥8.0 g\u002FdL (transfusion and\u002For growth factor support allowed)\n9. Fasting serum triglyceride must be ≤300 mg\u002FdL; fasting serum cholesterol must be less than or equal to 350 mg\u002FdL\n10. Minimum of 4 weeks since any major surgery, completion of radiation, and adequately recovered from the acute toxicities of any prior therapy, including neuropathy, to Grade ≤1\n11. Male or non-pregnant and non-breastfeeding female:\n\n    1. Females of childbearing potential must agree to use effective contraception or abstinence without interruption from 28 days prior to starting study medication throughout 3 months after last dose of study medication and have a negative serum pregnancy test (beta human chorionic gonadotropin \\[β-hCG\\]) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the EOS treatment. A second form of birth control is required even if she has had a tubal ligation.\n    2. Male patients must agree not to donate sperm and must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after last dose of study medication. A second form of birth control is required even if he has undergone a successful vasectomy.\n    3. Sexual abstinence is considered a highly effective contraceptive method only if defined as refraining from heterosexual intercourse from 28 days prior to starting study medication throughout 3 months after last dose of study medication. The reliability of sexual abstinence should be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient.\n12. The patient or the patient's legal guardian(s) understand(s) and sign(s) the informed consent\n13. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures\n14. Patients with a known history of human immunodeficiency virus (HIV) infection are eligible if:\n\n    1. There has been no acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection in 12 months prior to enrollment.\n    2. The patient has been receiving an antiretroviral therapy regimen for ≥4 weeks and the HIV viral load is \\\u003C400 copies\u002FmL prior to enrollment.\n    3. Antiretroviral therapy regimen does not include strong cytochrome (CYP)3A4 inhibitors or inducers\n\nExclusion Criteria:\n\n1. Prior treatment with mTOR inhibitors including nab-sirolimus\n\n   Note: Patients who have previously received locoregional or liver-directed therapies (radiofrequency or microwave ablation, transarterial chemoembolization, etc.) are eligible to enroll in the study.\n2. Patients with functional NETs who are experiencing uncontrolled symptoms attributed to hormones and other vasoactive substances secreted by the tumor\n3. Patients with inactivating TSC1 or TSC2 alterations (based on tissue or liquid NGS)\n4. Severe (Grade ≥3) ongoing infection requiring parenteral or oral anti-infective treatment, either ongoing or completed ≤7 days prior to enrollment\n5. Patients who have any severe and\u002For uncontrolled medical or psychiatric conditions or other conditions that could affect their participation including:\n\n   1. Known or suspected brain metastases\n   2. Severe heart disease defined as unstable angina pectoris, NYHA Class III or IV congestive heart failure, myocardial infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.\n   3. Severe lung disease defined as a diffusing capacity for carbon monoxide that is ≤50% of normal predicted value and\u002For an O2 saturation ≤88% at rest on room air\n\n      (Note: Spirometry and pulmonary function tests are not required to be performed unless clinically indicated.)\n   4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy\n   5. A history of malignancies other than the one under treatment unless the patient is disease-free for more than 5 years from diagnosis. Controlled non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, certain low-grade hematologic malignancies (eg, chronic lymphocytic leukemia, follicular lymphoma, etc), or other adequately treated carcinoma in situ may be eligible, after discussion with the medical monitor.\n   6. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg)\n   7. Patients with history of interstitial lung disease and\u002For pneumonitis, or pulmonary hypertension\n   8. Active Hepatitis B and\u002For Hepatitis C infection and detectable viral load despite antiviral therapy.\n6. Required use of concomitant medications with strong CYP3A4 interactions (induction or inhibition) should be discontinued (strong inhibitors include ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, telithromycin; strong inducers include rifampin and rifabutin). These agents must be discontinued prior to first dose of nab-sirolimus.",{"count":82,"type":20},[23],"A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors",[150,335,27,336,337],"NET","Gastrointestinal Neuroendocrine Tumor","Pulmonary Neuroendocrine Tumor",[339,340,341,150,335,27,336,337],"FYARRO","nab-sirolimus","ABI-009","2024-07-15",{"date":344,"type":39},"2024-07-16",{"date":346,"type":39},"2023-11-07",{"date":348,"type":20},"2025-12-08",{"name":350,"class":46},"Aadi Bioscience, Inc.",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":21,"phases":361,"briefSummary":362,"conditions":363,"keywords":366,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":378,"locationsCount":4},"100528949","comparison-of-kimura-versus-warshaw-technique-for-laparoscopic-spleen-preserving-distal-pancreatectomy-100528949","NCT06167421","Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy","Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy: A Multicenter Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age between 18 and 70 years, regardless of gender.\n* Preoperative clinical diagnosis of benign or low-grade malignant pancreatic tumors.\n* Meeting the recommended surgical indications as per guidelines.\n* Feasibility of imaging assessment for either Kimura or Warshaw technique laparoscopic spleen-preserving distal pancreatectomy.\n* Performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) score.\n* Willingness to comply with the study treatment plan, follow-up schedule, and other protocol requirements.\n* Voluntarily participating in the study and signing an informed consent form.\n\nExclusion Criteria:\n\n* Body Mass Index (BMI) \\> 28 kg\u002Fm2 (Chinese obesity standard).\n* History of blood disorders, acute or chronic pancreatitis, gastrointestinal bleeding, splenic rupture, or gastric varices (preoperative CT indicating curved vessel structures along the gastric wall with a diameter \\> 5mm).\n* History of abdominal surgery.\n* Concomitant primary malignant tumors.\n* Suspicion of malignancy based on PET-CT or other imaging examinations.\n* Severe impairment of cardiac, liver, or kidney function (NYHA class 3-4, ALT and\u002For AST exceeding three times the upper limit of normal, Creatinine exceeding the upper limit of normal).\n* Planned pregnancy or pregnancy and lactating women.\n* Participants currently involved in other clinical trials.","70 Years",{"count":360,"type":20},240,[59],"This study aims to compare the surgical outcomes of laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique versus the Warshaw technique. The primary focus is on the rates of unplanned splenectomy, occurrence of severe complications, as well as intraoperative and perioperative outcomes of both techniques.",[364,27,365],"Pancreatic Tumor, Benign","Solid Pseudopapillary Tumor of the Pancreas",[367,368,369,370,371],"Pancreatic benign or low-grade malignant tumors","Minimally invasive spleen-preserving distal pancreatectomy","Kimura technique","Warshaw technique","Prognosis","2023-12-04",{"date":374,"type":39},"2023-12-12",{"date":376,"type":20},"2024-01-01",{"date":70,"type":20},{"name":126,"class":73}]